

List of publications

1. Smith FG, Strack AM, de Wildt SN. Renal nerves do not modulate the renal and endocrine responses to furosemide in conscious lambs. *Can J Physiol Pharmacol* 1996;74(5):614-20.
2. Smith FG, Chan S, de Wildt SN. Effects of renal denervation on cardiovascular and renal responses to ACE inhibition in conscious lambs. *J Appl Physiol* 1997;83(2):414-9.
3. de Wildt SN, Smith FG. Effects of the angiotensin converting enzyme (ACE) inhibitor, captopril, on the cardiovascular, endocrine, and renal responses to furosemide in conscious lambs. *Can J Physiol Pharmacol* 1997;75(4):263-70.
4. van den Anker JN, de Wildt SN. Excessive terfenadine level due to drinking grapefruit juice. *Ned Tijdschr Geneeskd* 1997;141(41):1976-8.
5. de Wildt SN, van den Anker JN. Syncope with simultaneous use of terfenadine and itraconazole. *Ned Tijdschr Geneeskd* 1997;141(36):1752-3.
6. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. *Clin Pharmacokinet* 1999;36(6):439-52.
7. van Schaik RHN, de Wildt SN, Lindemans J. Cytochroom P450-polymorfismen en de behandeling van kanker. *Ned Tijdschr Klin Chem* 1999;24:232-237.
8. Kerkvliet CTM, Wezenberg MGA, de Wildt SN, Hop WCJ, van den Anker JN, Vulto AG. Bepaling in speeksel als alternatief voor plasmabepaling. *Pharmaceutisch Weekblad* 1999;134(42):1451-1453.
9. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. *Clin Pharmacokinet* 1999;37(6):485-505.
10. van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. *Clin Chem* 2000;46(11):1834-6.
11. de Wildt SN, Kerkvliet KT, Wezenberg MG, Ottink S, Hop WC, Vulto AG, et al. Use of saliva in therapeutic drug monitoring of caffeine in preterm infants. *Ther Drug Monit* 2001;23(3):250-4.
12. van Schaik RHN, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. The CYP3A4*3 allele: is it really rare? *Clin Chem* 2001;47(6):1104-6.
13. de Wildt SN, Kearns GL, Hop WCJ, Murry DJ, Abdel-Rahman SM, van den Anker JN Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Submitted
14. de Wildt SN, Kearns GL, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Submitted
15. de Wildt SN, de Hoog M, Vinks AA, van der Giesen E, van den Anker JN Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Submitted
16. de Wildt SN, van Schaik RHN, Kearns GL, van Iperen NM, Hop WCJ, Murry DJ, van den Anker JN Midazolam pharmacokinetics in preterm infants: lack of an association with the CYP3A4*1B genetic polymorphism. Submitted
17. de Wildt SN, Kearns GL, Sie SD, Hop WCJ, van den Anker JN Pharmacodynamics of intravenous and oral midazolam in preterm infants. Submitted
18. de Wildt SN, de Hoog M, Vinks AA, Joosten KFM, van den Anker JN Pharmacodynamics of midazolam in pediatric intensive care patients. Submitted